Bluejay Diagnostics (USA Stocks: BJDX) presents an interesting investment case from a valuation perspective. With a market capitalization of only
5.6M, the company seems undervalued considering its enterprise value of
153.9M. The company's book value per share stands at 0.45X, which is lower than the target price of 60, suggesting a potential upside. However, investors should also consider the company's
financial health. Bluejay reported a net income loss of 9.3M for the current fiscal year, which may raise concerns about its profitability. Additionally, the company's Z-Score of 3.75 indicates a low probability of bankruptcy, but its high insider ownership of 44.35% could be a red flag for potential investors. Lastly, the company's short position is relatively high at 1.13M shares, which could indicate that some investors are betting on a price decline.
Rigorous look
Bluejay Diagnostics currently possesses 492.62K in liabilities, with a Debt to Equity (D/E) ratio of 0.04. This may suggest that Bluejay Diagnostics is not leveraging debt as much as it could be. The company has a performance score of 6 on a scale from zero to one hundred. It also displays a Beta (market volatility) of 3.2731, indicating a somewhat significant risk relative to the broader market. As the market rises, the company is expected to outperform it. However, if the market generates negative returns, Bluejay Diagnostics will likely underperform.
It's important to consider Bluejay Diagnostics' historical returns, but one should also be prudent about what can be inferred from the current trending patterns of the equity. Our approach to predicting the future performance of any stock involves not only studying its past charts but also examining the business as a whole, including all fundamental and technical indicators.
In order to assess whether Bluejay Diagnostics' expected return of 1.31 will be sustainable in the future, we have identified twenty-seven different technical indicators. These can assist you in determining if the expected returns are viable. Utilize Bluejay Diagnostics' value at risk, as well as the relationship between skewness and the day median price to analyze future returns on Bluejay Diagnostics.
We determine the current worth of Bluejay Diagnostics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bluejay Diagnostics based exclusively on its
fundamental and basic
technical indicators. By analyzing Bluejay Diagnostics's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bluejay Diagnostics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bluejay Diagnostics. We calculate exposure to Bluejay Diagnostics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Bluejay Diagnostics's related companies.
Watch out for price decline
Please consider monitoring Bluejay Diagnostics on a daily basis if you are holding a position in it. Bluejay Diagnostics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Bluejay Diagnostics stock to be traded above the $1 level to remain listed. If Bluejay Diagnostics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Bluejay Diagnostics Investment Alerts
Bluejay investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Bluejay Diagnostics performance across your portfolios.Please check all
investment alerts for Bluejay
Bluejay Diagnostics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Bluejay value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bluejay Diagnostics competition to find
correlations between indicators driving the intrinsic value of Bluejay.
Bluejay Diagnostics Gross Profit
Bluejay Diagnostics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Bluejay Diagnostics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Bluejay Diagnostics Gross Profit growth over the last 10 years. Please check Bluejay Diagnostics'
gross profit and other
fundamental indicators for more details.
Is Bluejay Diagnostics valued reasonably by the market?
Bluejay Diagnostics reported the previous year's revenue of 249.04
K. Net Loss for the year was (9.3
M) with profit before overhead, payroll, taxes, and interest of 48.91
K.
Margins Breakdown
Bluejay profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Bluejay Diagnostics itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Bluejay Diagnostics profit margins.
| EBITDA Margin | (35.06) |
| Gross Margin | 0.18 |
| Profit Margin | (36.25) |
Bluejay Diagnostics Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 5 years. Further, Bluejay Diagnostics Free Cash Flow is decreasing over the last 5 years. The previous year's value of Bluejay Diagnostics Free Cash Flow was -9,176,149. Bluejay Diagnostics Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 5 years. The previous year's value of Bluejay Diagnostics Earnings Before Interest Taxes and Depreciation Amortization USD was -9,227,174. Further, Bluejay Diagnostics Free Cash Flow is decreasing over the last 5 years. The current value of Bluejay Diagnostics Free Cash Flow is -9,176,149.
Bluejay Diagnostics (USA Stocks: BJDX), a player in the Medical Devices industry, has been under the microscope recently for its potential market adjustment. The company, which currently has a market capitalization of
5.59 million, has been showing signs of financial strain with an EBITDA of
-9.7 million, indicating significant losses. The company's operating income also stands at a loss of -9.3 million. Despite these losses, Bluejay Diagnostics holds a robust current ratio of 17.41X, indicating its ability to meet short-term obligations. The company also maintains a healthy working capital of 10.15 million, supported by a substantial end period cash flow of 10.1 million. However, the company's earnings per share stand at a loss of -11.78, which is a concerning factor for potential investors. Furthermore, the company's free cash flow stands at -8.9 million, which could impact its ability to invest in growth opportunities. Interestingly, Wall Street's target price for the stock is 60, suggesting a potential upside. However, with a short percent of 0.0985 and shares short of 1.1 million, it seems some investors are betting against the stock. Given these factors, it remains to be seen whether Bluejay Diagnostics is indeed poised for a potential market adjustment. .
Our perspective of the current Bluejay Diagnostics rise
Despite the recent surge in Bluejay Diagnostics' stock, it's essential to scrutinize the underlying metrics. The Treynor ratio, a significant risk-adjusted performance measure, has declined to 0.18. While this may initially appear concerning, it's crucial to note that a lower Treynor ratio could suggest that the stock is less risky in relation to its market-related risk. This could indicate that the company's recent rise is more sustainable and less prone to market volatility. Therefore, we continue to maintain a positive outlook on Bluejay Diagnostics, as the current rise seems to be supported by robust
fundamentals rather than mere speculative trading. As of August 3rd, Bluejay Diagnostics displays a Mean Deviation of 8.92, a downside deviation of 8.75, and a Risk Adjusted Performance of 0.0402. Bluejay Diagnostics'
technical analysis provides a methodology to utilize historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. In other words, this information can be used to ascertain if the firm will indeed mirror its model of historical prices and volume momentum, or if the prices will eventually revert. We were able to analyze nineteen technical drivers for Bluejay Diagnostics, which can be compared to its
competitors.
Please verify Bluejay Diagnostics' variance, value at risk, as well as the relationship between the Value At Risk and skewness to determine if Bluejay Diagnostics is priced correctly, assuming the market reflects its regular price of 8.31 per share. Given that Bluejay Diagnostics has a Jensen Alpha of 0.4453, we recommend you to validate Bluejay Diagnostics's current market performance to ensure the company can sustain itself in the future. In conclusion, Bluejay Diagnostics has shown a significant rise of over 52 percent, and based on various data points, there's potential for further growth. The company's Valuation Market Value stands at
8.31, while the Analyst Overall Consensus rates it as a 'Strong Buy'. Out of the two estimates provided by analysts, the highest estimated target price is
80, suggesting a substantial upside potential. The Valuation Real Value of 21.26 also indicates that the stock is undervalued. However, investors should also consider the possible downside price of 0.0831. Given these factors, it seems plausible that Bluejay Diagnostics could continue its upward trajectory, but as always, investors should conduct their own thorough research before making any investment decisions. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Bluejay Diagnostics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com